Calreticulin exposure induced by anticancer drugs is associated with the p53 signaling pathway in colorectal cancer cells

被引:0
|
作者
Naito, Satoru [1 ]
Kajiwara, Taiki [1 ]
Karasawa, Hideaki [1 ]
Ono, Tomoyuki [1 ]
Saito, Tatsushi [1 ]
Funayama, Ryo [2 ]
Nakayama, Keiko [2 ]
Ohnuma, Shinobu [1 ]
Unno, Michiaki [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Surg, 1-1 Seiryo Machi,Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Tohoku Univ, Grad Sch Med, Dept Cell Proliferat, ART, Sendai, Japan
关键词
Calreticulin; Immunogenic cell death; p53; Organoid; MICROSATELLITE INSTABILITY; CHEMOTHERAPY; MECHANISMS; BLOCKADE;
D O I
10.1016/j.bbrc.2024.150665
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunogenic cell death (ICD) enhances immunogenicity and activates antitumor immune responses. ICD induction by anticancer drugs may be effective against microsatellite-stable colorectal cancers (CRCs) that are less responsive to immune checkpoint inhibitors. Calreticulin (CRT) is crucial in ICD, promoting dendritic cell phagocytosis and initiating antitumor immunity. This study investigated CRT exposure mechanisms in four CRC cell lines and three human CRC organoids. Flow cytometry and immunofluorescence showed that oxaliplatin and 5-fluorouracil caused CRT exposure in all models. Despite CRT's association with endoplasmic reticulum stress, Western blot analysis showed no increase in this stress. These findings suggest alternative pathways. RNA sequencing identified enrichment of p53 signaling pathway genes, including TP53I3, , TP53INP1, , and YPEL3, , which were confirmed by RT-qPCR. These results suggest that the p53 signaling pathway plays an important role in CRT exposure induced by anticancer drugs.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Novel evidence for the role of the p53 signaling pathway in mediating the anticancer effects of aronia berry extract in colorectal cancer cells
    Asahi, Yoh
    Okuno, Keisuke
    Xu, Caiming
    Taketomi, Aknobu
    Goel, Ajay
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [2] The Role of p53 Signaling in Colorectal Cancer
    Liebl, Magdalena C.
    Hofmann, Thomas G.
    [J]. CANCERS, 2021, 13 (09)
  • [3] Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugs
    Blagosklonny, MV
    Iglesias, A
    Zhan, ZR
    Fojo, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 244 (02) : 368 - 373
  • [4] Anticancer effect of involucrasin A on colorectal cancer cells by modulating the Akt/MDM2/p53 pathway
    Wei, Chengming
    Du, Jingjing
    Shen, Yunfu
    Wang, Zi
    Lin, Qianyu
    Chen, Junhe
    Zhang, Fuming
    Lin, Wanjun
    Wang, Zhibin
    Yang, Zhuya
    Ma, Wenzhe
    [J]. ONCOLOGY LETTERS, 2023, 25 (06)
  • [5] Anticancer drugs - Unleashing p53
    Kirkpatrick, P
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (02) : 111 - 111
  • [6] ROS/p38/p53/Puma signaling pathway is involved in emodin-induced apoptosis of human colorectal cancer cells
    Liu, Baorong
    Yuan, Bo
    Zhang, Lan
    Mu, Weimin
    Wang, Chongmin
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (09): : 15413 - 15422
  • [7] The p53-signaling pathway and colorectal cancer: Interactions between downstream p53 target genes and miRNAs
    Slattery, Martha L.
    Mullany, Lila E.
    Wolff, Roger K.
    Sakoda, Lori C.
    Samowitz, Wade S.
    Herrick, Jennifer S.
    [J]. GENOMICS, 2019, 111 (04) : 762 - 771
  • [8] P53: An ubiquitous target of anticancer drugs
    Blagosklonny, MV
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (02) : 161 - 166
  • [9] Genetic variants in p53 signaling pathway genes predict chemotherapy efficacy in colorectal cancer
    Zhang, Ke
    Meng, Yixuan
    Cao, Xiangming
    Xu, Ye
    Du, Mulong
    Wu, Yuan
    Liu, Lingxiang
    [J]. CANCER MEDICINE, 2019, 8 (07): : 3428 - 3436
  • [10] HMGA2 promotes resistance against paclitaxel by targeting the p53 signaling pathway in colorectal cancer cells
    Jiang, Haizhong
    Li, Xueying
    Zhou, Feng
    Xi, Yang
    Xu, Guoqiang
    [J]. HELIYON, 2024, 10 (11)